Loading clinical trials...
Loading clinical trials...
A Retrospective Evaluation of Effectiveness and Cost-effectiveness of Extrafine HFA-BDP Compared With Combination ICS/LABA Therapy in the Management of Asthma in a Representative Population of UK Primary Care Patients
Conditions
Interventions
Extra-fine hydrofluoroalkane-beclometasone dipropionate
ICS / LABA via separate pMDI and / or BAI inhalers
Locations
1
United Kingdom
General Practice Research Database
London, London, United Kingdom
Start Date
January 1, 1991
Primary Completion Date
June 1, 2007
Completion Date
February 1, 2010
Last Updated
October 4, 2012
NCT02327897
NCT07219173
NCT07486401
NCT04706988
NCT04639791
NCT06471257
Lead Sponsor
Research in Real-Life Ltd
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions